Optimal Dosing Strategies and Managing AEs
Panelists discuss how they dose talquetamab in clinical practice, comparing its administration schedule to other bispecific antibodies and addressing dosing-related challenges they encounter.
EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement
EP: 2.Optimal Dosing Strategies and Managing AEs
EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways
EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics
EP: 5.Bispecifics in R/R MM: AE Management and Sequencing
EP: 6.Future Perspectives in R/R MM
EP: 7.R/R MM Treatment Landscape: Role of Bispecifics
EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Video content above is promoted by the following;
- Briefly discuss your case details and share your initial thoughts.
- How are you currently dosing talquetamab?
- How does the dosing for talquetamab compare with other bispecifics?
- What are the challenges you are seeing?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
